Sichuan Kelun-Biotech Biopharmaceutical Co Ltd
HKEX:6990
If you don’t study any companies, you have the same success buying stocks as you do in a poker game if you bet without looking at your cards.
Utilize notes to systematically review your investment decisions. By reflecting on past outcomes, you can discern effective strategies and identify those that underperformed. This continuous feedback loop enables you to adapt and refine your approach, optimizing for future success.
Each note serves as a learning point, offering insights into your decision-making processes. Over time, you'll accumulate a personalized database of knowledge, enhancing your ability to make informed decisions quickly and effectively.
With a comprehensive record of your investment history at your fingertips, you can compare current opportunities against past experiences. This not only bolsters your confidence but also ensures that each decision is grounded in a well-documented rationale.
Do you really want to delete this note?
This action cannot be undone.
| 52 Week Range |
72.5
217.8
|
| Price Target |
|
We'll email you a reminder when the closing price reaches HKD.
Choose the stock you wish to monitor with a price alert.
This alert will be permanently deleted.
Sichuan Kelun-Biotech Biopharmaceutical Co Ltd
Total Equity
Sichuan Kelun-Biotech Biopharmaceutical Co Ltd
Total Equity Peer Comparison
Competitors Analysis
Latest Figures & CAGR of Competitors
| Company | Total Equity | CAGR 3Y | CAGR 5Y | CAGR 10Y | ||
|---|---|---|---|---|---|---|
|
S
|
Sichuan Kelun-Biotech Biopharmaceutical Co Ltd
HKEX:6990
|
Total Equity
¥2.3B
|
CAGR 3-Years
N/A
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
|
|
Beigene Ltd
HKEX:6160
|
Total Equity
¥25.1B
|
CAGR 3-Years
0%
|
CAGR 5-Years
16%
|
CAGR 10-Years
N/A
|
|
|
Akeso Inc
HKEX:9926
|
Total Equity
¥2.6B
|
CAGR 3-Years
-6%
|
CAGR 5-Years
43%
|
CAGR 10-Years
N/A
|
|
|
Beijing Wantai Biological Pharmacy Enterprise Co Ltd
SSE:603392
|
Total Equity
¥12.7B
|
CAGR 3-Years
71%
|
CAGR 5-Years
57%
|
CAGR 10-Years
N/A
|
|
|
Shanghai RAAS Blood Products Co Ltd
SZSE:002252
|
Total Equity
¥30.7B
|
CAGR 3-Years
6%
|
CAGR 5-Years
22%
|
CAGR 10-Years
24%
|
|
|
Chongqing Zhifei Biological Products Co Ltd
SZSE:300122
|
Total Equity
¥31.5B
|
CAGR 3-Years
26%
|
CAGR 5-Years
44%
|
CAGR 10-Years
29%
|
|
Sichuan Kelun-Biotech Biopharmaceutical Co Ltd
Glance View
Sichuan Kelun-Biotech Biopharmaceutical Co Ltd is a CN-based company operating in Biotechnology industry. The company is headquartered in Chengdu, Sichuan and currently employs 1,155 full-time employees. The company went IPO on 2023-07-11. Sichuan Kelun-Biotech Biopharmaceutical Co Ltd, formerly Sichuan Kelun Biotech Biopharmaceutical Co Ltd, is a China-based company mainly engaged in the research and development, production, and sales of drugs. The firm is mainly engaged in the research and development, production, and sales of biopharmaceuticals, chemical raw materials, and chemical drug formulations. The firm's products are mainly used for the treatment of breast cancer, non-small cell lung cancer, Gastrointestinal cancer and other non tumor diseases.
See Also
What is Sichuan Kelun-Biotech Biopharmaceutical Co Ltd's Total Equity?
Total Equity
2.3B
CNY
Based on the financial report for Dec 31, 2023, Sichuan Kelun-Biotech Biopharmaceutical Co Ltd's Total Equity amounts to 2.3B CNY.
You don't have any saved screeners yet
